# A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil

> **NCT06715254** · — · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 152 (actual)

## Conditions studied

- Tuberculosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06715254
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-23
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** Due to the limited availability of eligible patients who met the study's criteria, as well as there has not been a case of tuberculosis, the study was terminated early.
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715254, "A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06715254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*